Not FDA-approved2,3Evidence: Large human trials

Peginesatide1,2

Also called Omontys, Peginesatide acetate1,2

Key takeaway

Peginesatide is a synthetic, peptide-based drug that stimulates red blood cell production. FDA approved it as Omontys in 2012 for anemia from chronic kidney disease in adults on dialysis.2,4 In February 2013 its makers recalled all lots after reports of serious allergic reactions, including fatal anaphylaxis, and FDA withdrew the approval on February 13, 2019, at the company’s request.2 Large randomized trials found it as effective as older drugs at keeping hemoglobin up in people on dialysis, but cardiovascular events and deaths were higher with it in people not on dialysis.4,5

Peginesatide at a glance

What it isA pegylated synthetic peptide that acts as an erythropoiesis-stimulating agent, recorded by FDA’s substance registry as peginesatide and its acetate.1,4
FDA statusNot FDA-approved. FDA approved Omontys on March 27, 2012, and withdrew that approval as of February 13, 2019, after the company asked it to.2
Human evidenceFour randomized, open-label phase 3 trials: two in 1,608 people on hemodialysis and two in 983 people with chronic kidney disease not on dialysis.4,5
Evidence strengthLarge randomized human trials. The cited sources include at least one fully reported randomized, controlled human trial with 300 or more participants, or a trial that a regulator cites as a basis for approval. How this label is assigned

What is peginesatide?

Peginesatide is a synthetic peptide-based erythropoiesis-stimulating agent, a drug that prompts the body to make red blood cells. FDA’s substance registry records it as peginesatide and peginesatide acetate.1,4

In the United States it was the active ingredient of Omontys, NDA 202799, according to Drugs@FDA.3

How does peginesatide work?

Like epoetin and darbepoetin, it is an erythropoiesis-stimulating agent used to raise and maintain hemoglobin in people with anemia from advanced chronic kidney disease, according to the trial reports.4,5

What do human studies show?

In EMERALD 1 and 2, 1,608 people on hemodialysis received peginesatide or continued on epoetin for 52 weeks or more. Peginesatide was noninferior at maintaining hemoglobin, and cardiovascular safety was similar in a pooled analysis of the four trials.4

In PEARL 1 and 2, among 983 people with chronic kidney disease not on dialysis, it matched darbepoetin on hemoglobin, but cardiovascular events and deaths were higher with peginesatide.5

After approval, a dialysis organization that gave it to 19,540 patients reported anaphylaxis and low blood pressure at about 1.4 events per 1,000 patients, including five deaths, according to a 2014 letter.6

What the evidence base contains

  • Large randomized human trial EMERALD 1 and 2: randomized, controlled, open-label trials in 1,608 people on hemodialysis, in which peginesatide was noninferior to epoetin in maintaining hemoglobin.4
  • Large randomized human trial PEARL 1 and 2: randomized, controlled, open-label trials in 983 people with chronic kidney disease not on dialysis, in which it matched darbepoetin on hemoglobin but cardiovascular events and deaths were higher.5

Evidence-strength label: Large randomized human trials. How this label is assigned

Is peginesatide FDA-approved?

No. FDA approved Omontys, NDA 202799, on March 27, 2012, for anemia due to chronic kidney disease in adults on dialysis. On February 23, 2013, the makers voluntarily recalled all lots and suspended marketing after postmarketing reports of serious hypersensitivity reactions, including anaphylaxis, which can be fatal.2

At the company’s request, FDA’s approval of NDA 202799 was withdrawn as of February 13, 2019, according to FDA’s Federal Register notice.2

Drugs@FDA still lists Omontys products, as discontinued.3

FDA’s compounding safety-risk page, current as of April 22, 2026, does not list peginesatide.7

HHS’s October 30, 2026 draft enforcement-discretion policy lists six peptides in its Appendix A: BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500. Peginesatide is not among them.8,9

Timeline

  1. FDA approves Omontys, NDA 202799, according to FDA’s 2019 notice.2
  2. The EMERALD and PEARL trial reports are published.4,5
  3. The makers recall all lots of Omontys after reports of serious hypersensitivity reactions.2
  4. FDA’s withdrawal of approval of NDA 202799 takes effect, at the company’s request.2

What is still unknown?

Why serious allergic reactions appeared mainly after approval: the 2014 letter notes that the registration trials had shown no such signal.6

PeptideScanner reports what the cited sources say. It is not medical advice and does not recommend using, buying or dosing any substance. Read the full disclaimer.

Go deeper

Records, reviews and history

Everything PeptideScanner has collected for Peginesatide: reviews, official-source readings, registry and literature records, and every change to this profile.

What the trial and literature lists cover. The trials and papers listed for Peginesatide are a bounded selection, not every registration or paper about Peginesatide. For the years before Peginesatide was added, PeptideScanner took at most 25 ClinicalTrials.gov registrations that list Peginesatide as an intervention: trials with posted results first, then later-phase trials, then the most recently updated. It also took at most 25 PubMed papers that name Peginesatide in the title: randomized controlled trials, clinical trials, meta-analyses, systematic reviews and reviews first, then the most recent. Records that also named another tracked peptide, or that failed the publication checks, were left out. A daily check adds newly updated registrations and newly indexed papers that pass the same checks. How records are selected.

Status brief and reviewed-evidence summary

Evidence summary

What the cited records show

What is its status in the cited records?

FDA approval withdrawn in 2019 at the company’s request, after a 2013 recall. Large randomized trials found it matched older drugs on hemoglobin, with more cardiovascular events in people not on dialysis. Peginesatide is not on FDA’s compounding safety-risk page and is not among the six peptides in HHS’s October 2026 draft policy.↗↗↗↗↗↗

Status sources checked through November 14, 2026. See status sources and coverage →

Research records

Explore this profile’s cited source records →

An editorial human-evidence summary has not yet been published.

Explore status sources, recent additions, and coverage gaps

Living status brief

What is the current status of Peginesatide?

FDA approval withdrawn in 2019 at the company’s request, after a 2013 recall. Large randomized trials found it matched older drugs on hemoglobin, with more cardiovascular events in people not on dialysis. Peginesatide is not on FDA’s compounding safety-risk page and is not among the six peptides in HHS’s October 2026 draft policy.↗↗↗↗↗↗

The cited status sources were checked through November 14, 2026. This answer changes only through the profile’s visible version and correction history.

Evidence present

What records are connected here?

Evidence lanes
3
Source years
10
Drugs@FDA applications
1

These are counts in PeptideScanner’s selected public collection, not measures of research quality, medical relevance, safety, or effectiveness.

Coverage gaps

What remains unknown or unsupported?

PeptideScanner currently has no selected safety records connected to this profile. That is a collection gap, not evidence that no such records exist.

PeptideScanner does not infer an answer where the cited records do not provide one. Open the source-linked records below to inspect their scope and limits.

Explore the Evidence Map and record counts

Evidence Map v1

What kinds of records connect to Peginesatide?

Compare collection coverage →

This map describes PeptideScanner’s selected, source-linked collection. It is not an evidence grade and does not establish research quality, safety, effectiveness, or medical relevance.

34Selected dated records
43Connected citations
10Populated source years2011–2026
3/4Record lanes present

Registered human studies

Trial composition

14 of 14 selected trial records include at least one phase value; 14 of 14 include a status value in the retained structured contract.

PhasesPhase 2 8Phase 3 5Phase 1 1
Status at observationCompleted 14

PubMed bibliography

Publication composition

16 of 16 selected PubMed records include attributed title, venue, publication date, and publication-type fields.

Publication typesJournal Article 12Research Support, Non-U.S. Gov't 5Multicenter Study 4Comment 3Comparative Study 3Review 3Clinical Trial 2Clinical Trial, Phase III 2Editorial 2Letter 2Randomized Controlled Trial 2Clinical Trial, Phase II 1Validation Study 1

Regulatory and publication surfaces

What is structurally connected?

Drugs@FDA applications
1
FDA Federal Register documents
3
DailyMed SPL versions
0
Canonical profile
Published
Profile structured data
Published
Linked dated records
34

Application counts reflect exact reviewed ingredient connections; Federal Register counts reflect exact reviewed peptide-name matches; DailyMed counts reflect listed SPL versions with retained ZIP receipts. “Published” describes this page’s indexing surface, not the state of scientific evidence.

Profile publication history and record counts
Source records by collection · 34 dated records

Research hub

Explore the Peginesatide evidence record

Open all 34 records →
34Dated records
3Evidence types
34Cited public sources
10Source years

Change ledger

Recently changed for Peginesatide

Open all 34 events →

PeptideScanner change dates and cited source dates stay separate. These entries report collection or version activity, not a ranking of importance.

Record added

Federal Register notice 2011-27327

The Federal Register published notice 2011-27327, attributed to FDA and its parent HHS department, on 2011-10-24. Its official title is “Oncologic Drugs Advisory Committee; Notice of Meeting,” and PeptideScanner's exact reviewed identity mapping connects the document to Peginesatide.

PeptideScanner change date
November 17, 2026
Cited source date
October 24, 2011
Evidence lane
Regulatory
Record added

Federal Register notice 2014-11523

The Federal Register published notice 2014-11523, attributed to FDA and its parent HHS department, on 2014-05-20. Its official title is “Determination of Regulatory Review Period for Purposes of Patent Extension; OMONTYS,” and PeptideScanner's exact reviewed identity mapping connects the document to Peginesatide.

PeptideScanner change date
November 17, 2026
Cited source date
May 20, 2014
Evidence lane
Regulatory

Official-source collections

Source records for Peginesatide

Open the full research atlas →
PubMed16

16 with attributed title, venue, publication-date, and type metadata.

  1. Peginesatide for the treatment of anemia due to chronic kidney disease - an unfulfilled promise.Expert opinion on drug safety · 2016 08 23
  2. Watch out for a revival of peginesatide in sports.Drug testing and analysis · 2016 06 09
  3. Peginesatide to Manage Anemia in Chronic Kidney Disease Patients on Peritoneal Dialysis.Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis · 2014 03 01
Explore all selected literature →
ClinicalTrials.gov14

0 public history versions across these dated registry records; status labels apply only to each cited observation.

  1. NCT00314795Registry update March 14, 2019 · completed at observation
  2. NCT01478971Registry update September 20, 2016 · completed at observation
  3. NCT00597584Registry update March 8, 2013 · completed at observation
Explore all selected trial records →Explore all public record history →

Evidence types

Coverage by source year

Selected records span October 24, 2011 to November 9, 2026. These dates come from selected source records and PubMed metadata, not a complete or continuous timeline of research, safety, approval, or effectiveness.

Continue exploring

Profiles with overlapping source-year coverage

Open the research atlas →

These links are based only on overlapping years and evidence lanes in PeptideScanner’s selected records. They do not imply that the peptides are medically or scientifically similar.

Organizations and trial records named in cited sources

Organizations named in cited records

  • U.S. Food and Drug Administration1,2,3,7
  • U.S. Department of Health and Human Services8
Dated updates connected to this profile · 34

Updates connected to this profile

Open the full cross-source timeline →
  1. Literature metadata

    Peginesatide acetate, axitinib, and pertuzumab.↗

    PubMed lists PMID 23023854 in Journal of the American Pharmacists Association : JAPhA as Journal Article, Review, with publication-date metadata of 2012 Sep-Oct (source-text precision). PeptideScanner associated the retained record with the identity slug peginesatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  2. Literature metadata

    Peginesatide in patients with anemia undergoing hemodialysis.↗

    PubMed lists PMID 23343061 in The New England journal of medicine as Clinical Trial, Phase III, Comparative Study, Journal Article, Multicenter Study, Randomized Controlled Trial, and 1 more PubMed publication type, with publication-date metadata of 2013-01-24 (day precision). PeptideScanner associated the retained record with the identity slug peginesatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  3. Literature metadata

    Peginesatide for anemia in patients with chronic kidney disease not receiving dialysis.↗

    PubMed lists PMID 23343062 in The New England journal of medicine as Clinical Trial, Phase III, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, with publication-date metadata of 2013-01-24 (day precision). PeptideScanner associated the retained record with the identity slug peginesatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  4. Literature metadata

    Peginesatide (Omontys) for anemia in chronic kidney failure.↗

    PubMed lists PMID 22683926 in The Medical letter on drugs and therapeutics as Journal Article, with publication-date metadata of 2012-06-11 (day precision). PeptideScanner associated the retained record with the identity slug peginesatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  5. Literature metadata

    Peginesatide for maintenance treatment of anemia in hemodialysis and nondialysis patients previously treated with darbepoetin alfa.↗

    PubMed lists PMID 23243269 in Clinical journal of the American Society of Nephrology : CJASN as Clinical Trial, Comparative Study, Journal Article, Multicenter Study, Research Support, Non-U.S. Gov't, with publication-date metadata of 2012-12-14 (day precision). PeptideScanner associated the retained record with the identity slug peginesatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  6. Literature metadata

    Managing dialysis patients who develop anemia caused by chronic kidney disease: focus on peginesatide.↗

    PubMed lists PMID 24023516 in International journal of nanomedicine as Journal Article, Review, with publication-date metadata of 2013-08-26 (day precision). PeptideScanner associated the retained record with the identity slug peginesatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  7. Literature metadata

    Peginesatide to Manage Anemia in Chronic Kidney Disease Patients on Peritoneal Dialysis.↗

    PubMed lists PMID 24584613 in Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis as Clinical Trial, Clinical Trial, Phase II, Journal Article, Multicenter Study, Research Support, Non-U.S. Gov't, with publication-date metadata of 2014-03-01 (day precision). PeptideScanner associated the retained record with the identity slug peginesatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  8. Literature metadata

    Development and validation of a mass spectrometric detection method of peginesatide in dried blood spots for sports drug testing.↗

    PubMed lists PMID 22592927 in Analytical and bioanalytical chemistry as Journal Article, Research Support, Non-U.S. Gov't, Validation Study, with publication-date metadata of 2012-05-17 (day precision). PeptideScanner associated the retained record with the identity slug peginesatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  9. Clinical trials

    ClinicalTrials.gov record NCT00314795↗

    PeptideScanner retained ClinicalTrials.gov record NCT00314795 at 2026-11-16T17:45:11.119Z. Its registry update date was 2019-03-14, and PeptideScanner's reviewed identity mapping was peginesatide.↗

  10. Regulatory

    Federal Register notice 2019-02146↗

    The Federal Register published notice 2019-02146, attributed to FDA and its parent HHS department, on 2019-02-13. Its official title is “Takeda Pharmaceuticals U.S.A., Inc.; Withdrawal of Approval of a New Drug Application for OMONTYS (peginesatide) Injection,” and PeptideScanner's exact reviewed identity mapping connects the document to Peginesatide.↗

  11. Literature metadata

    Peginesatide for anemia in chronic kidney disease.↗

    PubMed lists PMID 23594010 in The New England journal of medicine as Letter, Comment, with publication-date metadata of 2013-04-18 (day precision). PeptideScanner associated the retained record with the identity slug peginesatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  12. Literature metadata

    Peginesatide for anemia in chronic kidney disease.↗

    PubMed lists PMID 23594011 in The New England journal of medicine as Letter, Comment, with publication-date metadata of 2013-04-18 (day precision). PeptideScanner associated the retained record with the identity slug peginesatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

Citations

Sources

Coverage and sources →

Numbered markers in the text point here. Each link opens the original public record.

  1. 1
    Peginesatide substance identity record ↗

    FDA Global Substance Registration System · Official source · Source checked November 16, 2026

  2. 2
    Takeda Pharmaceuticals U.S.A., Inc.; Withdrawal of Approval of a New Drug Application for OMONTYS (peginesatide) Injection (February 13, 2019) · FR Doc. 2019-02146 ↗

    Federal Register · Official source · Source checked November 16, 2026

  3. 3
    Drugs@FDA: OMONTYS (peginesatide acetate), NDA 202799 · original approval March 27, 2012 ↗

    U.S. Food and Drug Administration · Official source · Source checked November 16, 2026

  4. 4
    Peginesatide in patients with anemia undergoing hemodialysis (2013) · PMID 23343061 ↗

    The New England Journal of Medicine · Official source · Source checked November 16, 2026

  5. 5
    Peginesatide for anemia in patients with chronic kidney disease not receiving dialysis (2013) · PMID 23343062 ↗

    The New England Journal of Medicine · Official source · Source checked November 16, 2026

  6. 6
    Anaphylaxis and hypotension after administration of peginesatide (2014) · PMID 24849101 ↗

    The New England Journal of Medicine · Official source · Source checked November 16, 2026

  7. 7
    Certain bulk drug substances for use in compounding that may present significant safety risks ↗

    U.S. Food and Drug Administration · Official source · Source checked November 14, 2026

  8. 8
    Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances · notice of availability · 91 FR 68526 · October 30, 2026 ↗

    Federal Register · U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026

  9. 9
    HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, with Appendix A (list of peptides) and Appendix B (identities and justifications) ↗

    U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026